Program
felcorekibart
In GlaxoSmithKline's pipeline, Ultra long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody
. Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Nasal Polyps, led by GlaxoSmithKline.
Furthest: phase 3, since Aug 19, 20269 company-led studies, 9 open or runningNext primary completion: Apr 13, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 99 open or running | phase 3since Aug 19, 2026 | Dec 19, 2024 | Apr 13, 2027phase 1 · NCT07712393 |
- Named in GlaxoSmithKline’s own pipeline as
felcorekibart GSK5784283
, phase 3, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 19, 2024First study: phase 2 study in AsthmaFirst studyNCT06748053 · 307 enrolled · United States, Bulgaria, Canada and more
- Jul 14, 2026Phase 1 study in AsthmaNCT07712393 · 24 enrolled · United States
- Aug 19, 20266 phase 3 studiesPhase 3 reachedNCT07780669, NCT07780656, NCT07780643 and 3 more
- Oct 29, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07915791 · 279 planned
Ahead
- Apr 13, 2027Primary completion: phase 1 study in AsthmaNCT07712393
- Feb 15, 2029Primary completion: phase 3 study in AsthmaNCT07780643
- Mar 6, 2029Primary completion: phase 3 study in Nasal PolypsNCT07782970
- Mar 6, 2029Primary completion: phase 3 study in Nasal PolypsNCT07782957
TargetBeta
“Ultra long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody”the company's pipeline, read by Claude · source
Other programs on TSLP
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tezepelumabrule | AstraZeneca | phase 4 | 34 |
| tilrekimig | Pfizer | phase 3 | 11 |
| lunsekimig | Sanofi | phase 3 | 10 |
| SHR-1905 | Jiangsu HengRui Medicine | phase 3 | 7 |
| TQC2731 | Sino Biopharmaceutical | phase 3 | 7 |
| WIN378rule | windward-bio | phase 2 | 2 |
| CDX-622rule | Celldex Therapeutics | phase 1 | 2 |
| HXN-1013rule | Helixon Biotechnology (Suzhou) | phase 1 | 1 |
| HY6725rule | Newsoara Biopharma | phase 1 | 1 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07915791Pulmonary Disease, Chronic Obstructive | 2 | Not yet recruiting | Mar 16, 2029 | 279 |
| NCT07782996Asthma · United States, Japan | 3 | Recruiting | May 4, 2029 | 370 |
| NCT07782970Nasal Polyps · United States, Japan, Puerto Rico | 3 | Recruiting | Mar 6, 2029 | 218 |
| NCT07782957Nasal Polyps · United States, Australia | 3 | Recruiting | Mar 6, 2029 | 218 |
| NCT07780669Pulmonary Disease, Chronic Obstructive · United States, Japan | 3 | Recruiting | Jul 20, 2029 | 624 |
| NCT07780656Pulmonary Disease, Chronic Obstructive · United States, Argentina | 3 | Recruiting | Jul 20, 2029 | 624 |
| NCT07780643Asthma · United States | 3 | Recruiting | Feb 15, 2029 | 514 |
| NCT07712393Asthma · United States | 1 | Active, not recruiting | Apr 13, 2027 | 24 |
| NCT06748053Asthma · United States, Bulgaria, Canada and more | 2 | Active, not recruiting | Jul 14, 2026 | 307 |
How it is read
Names in the registry
- “GSK5784283”, 9 entries
Conditions, from the studies’ own filings
- Asthma, 4 studies
- Pulmonary Disease, Chronic Obstructive, 3 studies
- Nasal Polyps, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.